{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:16:52Z","timestamp":1789593412242,"version":"build-2803163510"},"reference-count":80,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives. Globally, hepatocellular carcinoma (HCC) is the sixth most prevalent cancer and represents the third leading cause of cancer-related mortality. Despite advances in diagnosis and treatment, the overall prognosis of HCC remains poor, largely due to late-stage presentation and high rates of vascular invasion. Portal vein thrombosis constitutes a significant complication of HCC, with an occurrence rate of 35\u201350%. Portal vein tumour thrombosis (PVTT) represents an aggressive form that is closely linked to decreased patient survival. The incidence of PVTT increases over time, from approximately 21% in the first year after diagnosis to nearly 46% by the third year, highlighting its high prevalence and progressive nature. The introduction of immunotherapy has marked a paradigm shift in the management of HCC. Immune checkpoint inhibitors, particularly those targeting the PD-1\/PD-L1 and CTLA-4 pathways, have demonstrated durable responses and significant survival benefits in certain patients with advanced HCC. Furthermore, emerging evidence suggests that combining immunotherapy with local or systemic therapies, such as trans arterial chemoembolization, hepatic arterial infusion chemotherapy, radiotherapy or tyrosine kinase inhibitors, may further enhance antitumor efficacy by modulating the tumour microenvironment and promoting synergistic immune activation. Method: This narrative review provides a comprehensive evaluation of immunotherapy in patients with HCC and PVTT, with a focus on its efficacy as both monotherapy and in combination with other treatment modalities in terms of tumour response, progression-free survival, and overall survival. It also addresses safety, patient selection, and emerging strategies to optimize outcomes in this high-risk population. Conclusions: The combination of multiple therapies could improve the patient\u2019s prognosis by achieving objective response rate of almost 82%, disease control rate of 97% and progression free survival of 12.9 months with quadruple therapy (HAIC-TACE combined with targeted and immunotherapy).<\/jats:p>","DOI":"10.3390\/cancers18040627","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T08:51:09Z","timestamp":1771491069000},"page":"627","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immunotherapy in Hepatocellular Carcinoma with Portal Vein Tumour Thrombosis: From Poor Prognosis to Curative-Intent Strategies"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8239-395X","authenticated-orcid":false,"given":"Luca","family":"Marzi","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Bolzano Regional Hospital (S\u00fcdtiroler Sanit\u00e4tsbetrieb\u2014Azienda Sanitaria dell\u2019Alto Adige SABES-ASDAA), 39100 Bolzano-Bozen, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9887-7315","authenticated-orcid":false,"given":"Rodolfo","family":"Sacco","sequence":"additional","affiliation":[{"name":"Gastroenterology and Digestive Endoscopy Unit, Foggia University Hospital, 71122 Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Siciliani","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9890-7011","authenticated-orcid":false,"given":"Saveria Lory","family":"Croc\u00e8","sequence":"additional","affiliation":[{"name":"Department of Medical, Surgical, and Health Sciences, University of Trieste, 34127 Trieste, Italy"},{"name":"Clinica Patologie Fegato, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), 34125 Trieste, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9910-3514","authenticated-orcid":false,"given":"Mauro","family":"Giuffr\u00e8","sequence":"additional","affiliation":[{"name":"Department of Medical, Surgical, and Health Sciences, University of Trieste, 34127 Trieste, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9146-9968","authenticated-orcid":false,"given":"Cristina","family":"Stasi","sequence":"additional","affiliation":[{"name":"Department of Life Science, Health and Health Professions, Link Campus University, 00165 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6129-6729","authenticated-orcid":false,"given":"Chiara","family":"Turri","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Bolzano Regional Hospital (S\u00fcdtiroler Sanit\u00e4tsbetrieb\u2014Azienda Sanitaria dell\u2019Alto Adige SABES-ASDAA), 39100 Bolzano-Bozen, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Zoeschg","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Bolzano Regional Hospital (S\u00fcdtiroler Sanit\u00e4tsbetrieb\u2014Azienda Sanitaria dell\u2019Alto Adige SABES-ASDAA), 39100 Bolzano-Bozen, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0458-3763","authenticated-orcid":false,"given":"Andrea","family":"Mega","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Bolzano Regional Hospital (S\u00fcdtiroler Sanit\u00e4tsbetrieb\u2014Azienda Sanitaria dell\u2019Alto Adige SABES-ASDAA), 39100 Bolzano-Bozen, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"key":"ref_1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.3748\/wjg.v21.i12.3462","article-title":"Management of hepatocellular carcinoma with portal vein thrombosis","volume":"21","author":"Quirk","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_3","unstructured":"European Association for the Study of the Liver (2018). EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol., 69, 182\u2013236."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.12771\/emj.2025.e4","article-title":"Management strategies for advanced hepatocellular carcinoma with portal vein tumor thrombosis","volume":"48","author":"Park","year":"2025","journal-title":"Ewha Med. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.livres.2024.09.002","article-title":"Portal vein tumor thrombosis in hepatocellular carcinoma patients: Is it the end?","volume":"8","author":"Abdelhamed","year":"2024","journal-title":"Liver Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1055-3207(02)00082-0","article-title":"Results of hepatic resection for hepatocellular carcinoma invading major portal and\/or hepatic veins","volume":"12","author":"Ikai","year":"2003","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"782","DOI":"10.21037\/hbsn-19-810","article-title":"A new staging system for hepatocellular carcinoma associated with portal vein tumor thrombus","volume":"10","author":"Lau","year":"2021","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S2468-1253(19)30178-5","article-title":"Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: Comparing east and west","volume":"4","author":"Lu","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000514174","article-title":"Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 Update","volume":"10","author":"Kudo","year":"2021","journal-title":"Liver Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.annonc.2021.02.014","article-title":"Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO clinical practice guidelines","volume":"32","author":"Vogel","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000503685","article-title":"Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus (2018 Edition)","volume":"9","author":"Cheng","year":"2020","journal-title":"Liver Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"iv238","DOI":"10.1093\/annonc\/mdy308","article-title":"Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Vogel","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1002\/hep.30490","article-title":"An Eastern Hepatobiliary Surgery Hospital\/Portal Vein Tumor Thrombus Scoring System as an Aid to Decision Making on Hepatectomy for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Multicenter Study","volume":"69","author":"Zhang","year":"2019","journal-title":"Hepatology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"102547","DOI":"10.1016\/j.jceh.2025.102547","article-title":"Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma in 2025","volume":"15","author":"Kumar","year":"2025","journal-title":"J Clin Exp Hepatol"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"Sangro","year":"2017","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Liu, H.T., Jiang, M.J., Deng, Z.J., Li, L., Huang, J.L., Liu, Z.X., Li, L.Q., and Zhong, J.H. (2021). Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges. Front Oncol., 11.","DOI":"10.3389\/fonc.2021.737497"},{"key":"ref_20","first-page":"1016","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"386","author":"Lau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s13691-024-00683-5","article-title":"A patient who underwent conversion surgery after atezolizumab plus bevacizumab for hepatocellular carcinoma with portal vein thrombosis and perihepatic lymph node metastases achieved a pathological complete response","volume":"13","author":"Okuno","year":"2024","journal-title":"Int. Cancer Conf. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/HEP.0000000000001182","article-title":"Distinct immune microenvironment of venous tumor thrombus in hepatocellular carcinoma at single-cell resolution","volume":"82","author":"Zhou","year":"2025","journal-title":"Hepatology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"134","DOI":"10.17998\/jlc.2024.09.26","article-title":"Durable complete response after discontinuation of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma with portal vein tumor thrombosis: The first report","volume":"25","author":"Kumar","year":"2024","journal-title":"J. Liver Cancer"},{"key":"ref_24","first-page":"655","article-title":"Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and\/or Contralateral Portal Vein Invasion in IMbrave150","volume":"13","author":"Finn","year":"2024","journal-title":"Liver Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.17998\/jlc.2023.12.25","article-title":"Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis","volume":"24","author":"Park","year":"2024","journal-title":"J. Liver Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ccr.2012.07.023","article-title":"TGF-\u03b2-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma","volume":"22","author":"Yang","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4316","DOI":"10.7150\/thno.82907","article-title":"Erythroid-transdifferentiated myeloid cells promote portal vein tumor thrombus in hepatocellular carcinoma","volume":"13","author":"Zhu","year":"2023","journal-title":"Theranostics"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/0008-5472.CAN-15-0977","article-title":"Hypoxia-Induced Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma Induces an Immunosuppressive Tumor Microenvironment to Promote Metastasis","volume":"76","author":"Ye","year":"2016","journal-title":"Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Komatsu, S., Fujishima, Y., Kido, M., Kuramitsu, K., Goto, T., Yanagimoto, H., Toyama, H., and Fukumoto, T. (2021). Significant response to atezolizumab plus bevacizumab treatment in unresectable hepatocellular carcinoma with major portal vein tumor thrombus: A case report. BMC Gastroenterol., 21.","DOI":"10.1186\/s12876-021-02053-4"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12957-022-02691-2","article-title":"Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: A case report","volume":"20","author":"Hidaka","year":"2022","journal-title":"World J. Surg. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000529405","article-title":"Pathologic Complete Response After Chemotherapy with Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma with Tumor Thrombus in the Main Portal Trunk","volume":"40","author":"Kurisaki","year":"2023","journal-title":"Dig. Surg."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.ajt.2024.01.007","article-title":"Atezolizumab plus bevacizumab as a downstaging therapy for liver transplantation in hepatocellular carcinoma with portal vein thrombosis: The first report","volume":"24","author":"Kumar","year":"2024","journal-title":"Am. J. Transplant."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1007\/s00595-025-03009-x","article-title":"The potential efficacy of atezolizumab plus bevacizumab treatment for hepatocellular carcinoma patients with macroscopic portal vein tumor thrombus","volume":"55","author":"Komatsu","year":"2025","journal-title":"Surg. Today"},{"key":"ref_34","first-page":"1","article-title":"Camrelizumab Combined with Apatinib for Portal Vein Tumor Thrombus in Advanced Hepatocellular Carcinoma: Two Case Reports","volume":"85","author":"Chen","year":"2024","journal-title":"Br. J. Hosp. Med."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Zhong, K., Xu, Y., Cheng, Y., Wen, Y., Cai, L., He, G., Huang, H., Fu, S., Zhong, X., and Zheng, Y. (2022). Case report: Primary hepatocellular carcinoma with portal vein tumor thrombus characterized by active tumor immune microenvironment achieving a complete response following treatment of combined immunotherapy. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.999763"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s00262-020-02845-9","article-title":"Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis","volume":"70","author":"Tsai","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.12998\/wjcc.v12.i16.2847","article-title":"Conversion therapy of a giant hepatocellular carcinoma with portal vein thrombus and inferior vena cava thrombus: A case report and review of literature","volume":"12","author":"Song","year":"2024","journal-title":"World J. Clin. Cases"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1007\/s00261-024-04490-7","article-title":"A real-world study of tyrosine kinase inhibitors plus anti-PD-1 immunotherapy with or without chemoembolization for hepatocellular carcinoma patients with main portal vein invasion","volume":"49","author":"Song","year":"2024","journal-title":"Abdom. Radiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1097\/JS9.0000000000000256","article-title":"TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: A propensity score matching study","volume":"109","author":"Yuan","year":"2023","journal-title":"Int. J. Surg."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"You, R., Cheng, Y., Diao, L., Wang, C., Leng, B., Yu, Z., Xu, Q., and Yin, G. (2024). Immune-Targeted Therapy with or without Transarterial Chemoembolization (TACE) for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis (PVTT): A Multicenter Retrospective Study. Biomedicines, 12.","DOI":"10.3390\/biomedicines12092124"},{"key":"ref_41","first-page":"5455","article-title":"Clinical efficacy of HAIC (FOLFOX) combined with lenvatinib plus PD-1 inhibitors vs. TACE combined with lenvatinib plus PD-1 inhibitors in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas","volume":"13","author":"Lin","year":"2023","journal-title":"Am. J. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3892\/ol.2025.15109","article-title":"Efficacy of transarterial chemoembolization-hepatic arterial infusion chemotherapy combined with targeted therapy and immunotherapy in hepatocellular carcinoma with portal vein tumor thrombosis","volume":"30","author":"Hou","year":"2025","journal-title":"Oncol. Lett."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Chang, X., Li, X., Sun, P., Li, Z., Sun, P., and Ning, S. (2024). HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: A real-world study. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-12233-6"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00270-024-03724-x","article-title":"Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors Versus Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma with First- or Lower-Order Portal Vein Tumor Thrombosis","volume":"47","author":"Zhang","year":"2024","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"69","DOI":"10.17998\/jlc.2022.03.09","article-title":"Concurrent transarterial radioembolization and combination atezolizumab\/bevacizumab treatment of infiltrative hepatocellular carcinoma with portal vein tumor thrombosis: A case report","volume":"22","author":"Park","year":"2022","journal-title":"J. Liver Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.2147\/JHC.S479810","article-title":"Neoadjuvant-Based Triple Therapy for Hepatocellular Carcinoma with Type I\/II Portal Vein Tumor Thrombosis","volume":"11","author":"Hou","year":"2024","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.4143\/crt.2023.1165","article-title":"Efficacy of Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Retrospective, Multicenter Study","volume":"56","author":"Ou","year":"2024","journal-title":"Cancer Res. Treat."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1007\/s00262-023-03511-6","article-title":"Transarterial interventional therapy combined with tyrosine kinase inhibitors with or without anti-PD-1 antibodies as initial treatment for hepatocellular carcinoma with major portal vein tumor thrombosis: A single-center retrospective study","volume":"72","author":"Yu","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s12672-024-01026-9","article-title":"Interventional therapy combined with tyrosine kinase inhibitors with or without immune checkpoint inhibitors as initial treatment for hepatocellular carcinoma with portal vein tumor thrombosis: A systematic review and meta-analysis","volume":"15","author":"Du","year":"2024","journal-title":"Discov. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3892\/ol.2025.14868","article-title":"Efficacy and safety of neoadjuvant therapy for hepatocellular carcinoma with portal vein thrombosis: A meta-analysis","volume":"29","author":"Xuan","year":"2025","journal-title":"Oncol. Lett."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Jiao, T., Tang, H., Zhang, W., Hu, B., Wan, T., Cao, Y., Zhang, Z., Wang, Y., Cao, J., and Cui, M. (2023). Long-term survival and portal vein patency with novel PVTT surgery approach in advanced HCC patients with Vp3\/4 PVTT following combination therapy of TKIs and PD-1 inhibitors. BMC Surg., 23.","DOI":"10.1186\/s12893-023-02291-1"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Li, C., Liao, W., Huang, Y., and Wang, Z. (2022). A Combination of Sorafenib, an Immune Checkpoint Inhibitor, TACE and Stereotactic Body Radiation Therapy Versus Sorafenib and TACE in Advanced Hepatocellular Carcinoma Accompanied by Portal Vein Tumor Thrombus. Cancers, 14.","DOI":"10.3390\/cancers14153619"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"6942","DOI":"10.1097\/JS9.0000000000002890","article-title":"Sequential HAIC-TACE combined with targeted and immunotherapy in hepatocellular carcinoma: A quality improvement study","volume":"111","author":"Wan","year":"2025","journal-title":"Int. J. Surg."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1097\/JS9.0000000000002326","article-title":"Systemic therapy plus HAIC versus systemic therapy for hepatoellular carcinoma: A systematic review and meta-analysis","volume":"111","author":"Lu","year":"2025","journal-title":"Int. J. Surg."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"39494","DOI":"10.1038\/s41598-025-23027-6","article-title":"Locoregional therapy combined with targeted therapy and immunotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: A systematic review and meta-analysis","volume":"15","author":"Jiang","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"11315","DOI":"10.1002\/cam4.5841","article-title":"Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features","volume":"12","author":"Zou","year":"2023","journal-title":"Cancer Med."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Liu, B., Yin, L., Chen, Y., Hou, X., Li, Y., Liu, X., and Liu, R. (2025). Efficacy and safety of TACE-HAIC combined with tyrosine kinase inhibitors and immune checkpoint inhibitors for the patients with BCLC-defined stage B-C HCC. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1615506"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Li, Y., Wang, D., Zhang, F., Zheng, X., Song, Y., Ran, Y., and Cai, X. (2025). Hepatic arterial infusion chemotherapy combined with lenvatinib and toripalimab for large hepatocellular carcinoma (>10 cm) with major portal vein tumor thrombosis: A multicenter propensity score matching analysis. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1638173"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"843","DOI":"10.3748\/wjg.v30.i8.843","article-title":"Transcatheter arterial chemoembolization combined with PD-1 inhibitors and Lenvatinib for hepatocellular carcinoma with portal vein tumor thrombus","volume":"30","author":"Wu","year":"2024","journal-title":"World J. Gastroenterol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Liu, Q., Zhang, Y., Zhang, J., Chen, L., Yang, Y., and Liu, Y. (2024). Efficacy and safety of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis in the main trunk. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1374149"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00535-023-01976-x","article-title":"Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis","volume":"58","author":"Fu","year":"2023","journal-title":"J. Gastroenterol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Cao, F., Wen, C., Wang, Y., Tan, H., Hao, S., Chen, J., Chen, S., Shen, L., Xie, L., and Qi, H. (2025). PD-1 inhibitor-augmented HAIC-TKI therapy in hepatocellular carcinoma with portal vein tumor thrombosis: Real-world survival benefits, safety, and subgroup-specific efficacy. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1602031"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.21873\/invivo.13639","article-title":"Similar Efficacy Between Atezolizumab Plus Bevacizumab Versus Hepatic Arterial Infusion Chemotherapy For Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Retrospective Cohort Study","volume":"38","author":"Kuwano","year":"2024","journal-title":"In Vivo"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.2147\/JHC.S428980","article-title":"Transarterial Chemoembolization Plus Lenvatinib and PD-1 Inhibitors for Hepatocellular Carcinoma with Main Trunk Portal Vein Tumor Thrombus: A Multicenter Retrospective Study","volume":"10","author":"Li","year":"2023","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"17588359241231252","DOI":"10.1177\/17588359241231252","article-title":"Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy for hepatocellular carcinoma patients with portal vein tumor thrombus","volume":"16","author":"Li","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e7105","DOI":"10.1002\/cam4.7105","article-title":"Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma","volume":"13","author":"Fu","year":"2024","journal-title":"Cancer Med."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Lee, S.K., Kwon, J.H., Lee, S.W., Lee, H.L., Kim, H.Y., Kim, C.W., Song, D.S., Chang, U.I., Yang, J.M., and Nam, S.W. (2023). A Real-World Comparative Analysis of Atezolizumab Plus Bevacizumab and Transarterial Chemoembolization Plus Radiotherapy in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis. Cancers, 15.","DOI":"10.3390\/cancers15174423"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"225","DOI":"10.17998\/jlc.2023.02.27","article-title":"Favorable response of hepatocellular carcinoma with portal vein tumor thrombosis after radiotherapy combined with atezolizumab plus bevacizumab","volume":"23","author":"Kim","year":"2023","journal-title":"J. Liver Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"oyae209","DOI":"10.1093\/oncolo\/oyae209","article-title":"Radiotherapy with targeted and immunotherapy improved overall survival and progression-free survival for hepatocellular carcinoma with portal vein tumor thrombosis","volume":"30","author":"Ma","year":"2025","journal-title":"Oncologist"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Tang, C., He, Q., Feng, J., Liao, Z., Peng, Y., and Gao, J. (2023). Portal vein tumour thrombosis radiotherapy improves the treatment outcomes of immunotherapy plus bevacizumab in hepatocellular carcinoma: A multicentre real-world analysis with propensity score matching. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1254158"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Wang, K., Xiang, Y.J., Yu, H.M., Cheng, Y.Q., Liu, Z.H., Zhong, J.Y., Feng, S., Ni, Q.Z., Zhu, H.F., and Pan, W.W. (2023). Intensity-modulated radiotherapy combined with systemic atezolizumab and bevacizumab in treatment of hepatocellular carcinoma with extrahepatic portal vein tumor thrombus: A preliminary multicenter single-arm prospective study. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1107542"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1007\/s00261-024-04620-1","article-title":"Efficacy of radiotherapy combined with hepatic arterial infusion chemotherapy, TKI and ICI for hepatocellular carcinoma with portal vein tumor thrombus: A retrospective cohort study","volume":"50","author":"Tan","year":"2025","journal-title":"Abdom. Radiol."},{"key":"ref_73","first-page":"246","article-title":"Efficacy and Safety of Hypofractionated Radiation Therapy Combined with Immunotherapy for Hepatocellular Carcinoma with Vp4 Portal Vein Tumor Thrombosis","volume":"56","author":"Fujiwara","year":"2025","journal-title":"Hepatol. Res."},{"key":"ref_74","unstructured":"ClinicalTrials.gov ID NCT06669377 (2026, January 01). TACE Combined with ICIs Plus MTT After 125I Irradiation Stent Placement in HCC with Main PVTT. Last Update Posted 1 November 2024, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06669377?cond=NCT06669377&rank=1."},{"key":"ref_75","unstructured":"ClinicalTrials.gov ID NCT05166239 (2026, January 01). HAIC Combine with Lenvatinib and PD-1 Inhibitors for Advanced HCC with PVTT. Last Update Posted 2 May 2024, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05166239?cond=NCT05166239&rank=1."},{"key":"ref_76","unstructured":"ClinicalTrials.gov ID NCT07062055 (2026, January 01). BRAVE Study: QL1706 + Bevacizumab + SBRT for BCLC-C HCC with PVTT or Oli-gometastases, Available online: https:\/\/clinicaltrials.gov\/study\/NCT07062055?cond=NCT07062055&rank=1."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Xiao, Y., Li, K., Zhao, Y., Yang, S., Yan, J., Xiang, C., Zeng, J., Lu, Q., Zhang, C., and Li, G. (2024). Efficacy of radiotherapy in combined treatment of hepatocellular carcinoma patients with portal vein tumor thrombus: A real-world study. BMC Surg., 24.","DOI":"10.1186\/s12893-024-02334-1"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"109244","DOI":"10.1016\/j.intimp.2022.109244","article-title":"Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis","volume":"112","author":"Zheng","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","article-title":"Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma","volume":"28","author":"Zhu","year":"2022","journal-title":"Nat. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"218205","DOI":"10.1016\/j.canlet.2025.218205","article-title":"G6PD+ CSV+ circulating tumor cells associated with portal vein tumor thrombus formation via EMT-ferroptosis crosstalk: A dual biomarker for therapeutic efficacy and prognosis prediction in hepatocellular carcinoma","volume":"639","author":"Chen","year":"2026","journal-title":"Cancer Lett."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/4\/627\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T09:54:08Z","timestamp":1772013248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/4\/627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":80,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["cancers18040627"],"URL":"https:\/\/doi.org\/10.3390\/cancers18040627","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]}}}